Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4

Direct-acting antiviral drugs to cure infections with Hepatitis C virus (HCV) achieve a sustained virological response (SVR) in more than 90% of adult patients. At present, clinical trials are ongoing and real-life data are still limited in children. Herein, we report two cases of pediatric patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Marascio, Nadia, Mazzitelli, Maria, Pavia, Grazia, Giancotti, Aida, Barreca, Giorgio Settimo, Costa, Chiara, Pisani, Vincenzo, Greco, Giuseppe, Serapide, Francesca, Trecarichi, Enrico Maria, Casalinuovo, Francesco, Liberto, Maria Carla, Matera, Giovanni, Torti, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562692/
https://www.ncbi.nlm.nih.gov/pubmed/31060315
http://dx.doi.org/10.3390/cells8050416
Descripción
Sumario:Direct-acting antiviral drugs to cure infections with Hepatitis C virus (HCV) achieve a sustained virological response (SVR) in more than 90% of adult patients. At present, clinical trials are ongoing and real-life data are still limited in children. Herein, we report two cases of pediatric patients treated with fixed-dose combination of sofosbuvir/ledipasvir, already approved to treat HCV4 genotype. Both young girls achieved SVR even though HCV4 isolates carried L28M and M31L NS5A resistance-associated substitutions (RASs). Therefore, possible effects of these RASs merit further study, especially in children.

Ejemplares similares